In this issue:
Rectal tacrolimus for induction in resistant ulcerative proctitis
Risankizumab for moderate-tosevere CD
Biologicals for induction and maintenance of mucosal healing in IBD
Impact of pregnancy on anti-TNF pharmacokinetics in IBD
Safety of vedolizumab for IBD
Vedolizumab exposure in pregnancy
Vedolizumab effective in UC, regardless of anti-TNF experience
T. suis ova for active CD
Please login below to download this issue (PDF)